YANG Yi-ge, LI He, ZHANG Xiu-li, TAN Xiao-chuan, ZHANG Yu-jia, ZHENG Wen-sheng. Progress on research and development of drug for chronic kidney disease and related comorbiditiesJ. Acta Pharmaceutica Sinica, 2022, 57(9): 2682-2695. DOI: 10.16438/j.0513-4870.2022-0134
Citation: YANG Yi-ge, LI He, ZHANG Xiu-li, TAN Xiao-chuan, ZHANG Yu-jia, ZHENG Wen-sheng. Progress on research and development of drug for chronic kidney disease and related comorbiditiesJ. Acta Pharmaceutica Sinica, 2022, 57(9): 2682-2695. DOI: 10.16438/j.0513-4870.2022-0134

Progress on research and development of drug for chronic kidney disease and related comorbidities

  • Chronic kidney disease (CKD) is a progressive disease with many complications (eg, cardiovascular disease and acidosis and anemia) and high morbidity and mortality occurs in the population. There is no cure for this disease, current treatments including renin-angiotensin-aldosterone pathway inhibitors and sodium-glucose co-transporter 2 inhibitors can only delay the progression to end-stage renal disease. With the identification of more key factors and mechanisms in CKD development, new potential therapeutic approaches for CKD can be developed. This review summarizes the mainstays of therapy and strategies for CKD and related comorbidities to support the development of novel treatments.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return